Induction of glutathione biosynthesis by glycine-based treatment mitigates atherosclerosis.

ABSTRACT: Lower circulating levels of glycine are consistently reported in association with cardiovascular disease (CVD), but the causative role and therapeutic potential of glycine in atherosclerosis, the underlying cause of most CVDs, remain to be established. Here, following the identification of reduced circulating glycine in patients with significant coronary artery disease (sCAD), we investigated a causative role of glycine in atherosclerosis by modulating glycine availability in atheroprone mice. We further evaluated the atheroprotective potential of DT-109, a recently identified glycine-based compound with dual lipid/glucose-lowering properties. Glycine deficiency enhanced, while glycine supplementation attenuated, atherosclerosis development in apolipoprotein E-deficient (Apoe^-/-

SUBMITTER: Rom O 

PROVIDER: S-EPMC9044008 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature